Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

PHASE2RecruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

July 5, 2023

Primary Completion Date

October 1, 2026

Study Completion Date

October 1, 2029

Conditions
Pancreatic CancerHepatocellular CancerBiliary Tract CancerCholangiocarcinoma
Interventions
BIOLOGICAL

Durvalumab

It is a human immunoglobulin G1 kappa monoclonal antibody that blocks the interaction of programmed cell death ligand 1 with the PD-1. Durvalumab is known as a checkpoint inhibitor drug

DRUG

Gemcitabine

Gemcitabine is a nucleoside analog and a chemotherapeutic agent. As a prodrug, gemcitabine is transformed into its active metabolites that work by replacing the building blocks of nucleic acids during DNA elongation, arresting tumour growth and promoting apoptosis of malignant cells

DRUG

Nab paclitaxel

Nanoparticle albumin-bound (nab) paclitaxel is a form of paclitaxel which works as an antimicrotubule agent. Paclitaxel, the active ingredient in nab-paclitaxel promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This interferes with the normal dynamic reorganization of the microtubule network required for interphase and mitotic functions

BIOLOGICAL

Tremelimumab

Tremelimumab is a fully human monoclonal antibody against CTLA-4. It is an immune checkpoint blocker.

DRUG

Propranolol

Competitively blocks both β1 and β2 adrenergic receptors.

DRUG

Cisplatin

cisplatin has been associated with ability to crosslink with the urine bases on the DNA to form DNA adducts, preventing repair of the DNA leading to DNA damage and subsequently induces apoptosis within cancer cells.

Trial Locations (1)

Unknown

RECRUITING

Cross Cancer Institute, Edmonton

All Listed Sponsors
lead

AHS Cancer Control Alberta

OTHER